Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for ARQT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 12.48M
March 31, 2026 2.239M
December 31, 2025 26.18M
September 30, 2025 -1.754M
June 30, 2025 -9.754M
March 31, 2025 -30.99M
December 31, 2024 -5.748M
September 30, 2024 -34.83M
June 30, 2024 -45.12M
March 31, 2024 -31.60M
December 31, 2023 -56.25M
September 30, 2023 -44.05M
June 30, 2023 -66.76M
March 31, 2023 -80.43M
December 31, 2022 -71.19M
September 30, 2022 -75.20M
Date Value
June 30, 2022 -62.06M
March 31, 2022 -57.10M
December 31, 2021 -51.97M
September 30, 2021 -41.02M
June 30, 2021 -35.87M
March 31, 2021 -46.76M
December 31, 2020 -32.25M
September 30, 2020 -34.27M
June 30, 2020 -25.78M
March 31, 2020 -21.05M
December 31, 2019 -18.16M
September 30, 2019 -10.95M
June 30, 2019 -8.171M
March 31, 2019 -7.257M
December 31, 2018 -5.838M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 95.69M
Insmed, Inc. -95.09M
Emergent BioSolutions, Inc. 54.00M
Exelixis, Inc. 300.92M
Vertex Pharmaceuticals, Inc. 1.013B